Up Close and Personal With Jeff Plomley
Jeff received his graduate degree in Chemistry from Queens University. He focused the first decade of his career in mass spectrometry on instrumentation research and product development, designing novel scan functions for both 2D and 3D ion traps.
Hybridization LC-MS/MS Workflow to Quantify an siRNA Drug Candidate in Plasma, CSF, and Tissues
ISSUE NO. 31 — The Advantages of Conducting Early-Phase Clinical Research in Canada
Timely completion of necessary studies is a critical element of drug development, bringing important treatments to patients in a safe and cost-efficient way. A consideration with a measurable impact on early-phase clinical studies is the location where trials are performed; this is especially true for first-in-human (FIH) trials.
Conducting early-phase clinical research on novel compounds in Canada can provide significant advantages versus other locations.
In Issue 31 of The Altascientist, we take a deep dive into these advantages, covering:
- Canadian CTA trials–time and cost savings
- Regulatory review process predictability
- Business efficiency cost savings
- Clinical trial participants
Scratching the Surface of Dermal Testing
Dr. Keyhani Reflects on International Day of Women and Girls in Science
Opinion | A Day to Celebrate, and a Call to Action
Dr.
Case Study―Evaluating Milling Conditions for Scaling Up a Nanosuspension Drug Product
New Generation Pain Relief Without Opioids
Opioids are highly effective at relieving both acute and chronic pain. However, this benefit comes at a significant cost: they are also highly addictive.
2022 Year in Review
|